title: Potential implications of the choice among three alternative treatment targets for apolipoprotein B100 in the management of patients with type 2 diabetes and chronic kidney disease.
abstract: This study analyses discordance rates between attainment of therapeutic goals for apolipoprotein B100 (apoB) and both low-density lipoprotein-cholesterol (LDL-C) and non-high-density lipoprotein-cholesterol (non-HDL-C) in a sample of 152 patients with type 2 diabetes and chronic kidney disease from Gran Canaria (Spain), using treatment targets recommended by the American Diabetes Association/American College of Cardiology (ADA/ACC), the European Society of Cardiology/European Atherosclerosis Society (ESC/EAS) and by a Spanish population-based study. Among subjects with LDL-C levels at therapeutic goal, apoB was above target in 16.3% (ADA/ACC), 6.5% (ESC/EAS) and 39.1% (population-based criteria), and among subjects with non-HDL-C levels at therapeutic goal, apoB was above target in 10.5% (ADA/ACC), 1.2% (ESC/EAS) and 29.6% (population-based criteria). These findings show that clinical management would be very differently altered depending on the criteria used to set treatment targets for apoB. Cut-off points derived from population data identify a greater number of subjects suitable for a more intensive lipid-lowering therapy.
authors.affiliation: Section of Endocrinology and Nutrition, Hospital Universitario Insular, Las Palmas de Gran Canaria, Spain.
authors.forename: Mauro
authors.initials: M
authors.lastname: Boronat
authors.forename: César
authors.initials: C
authors.lastname: García-Cantón
authors.forename: Laura
authors.initials: L
authors.lastname: López-Ríos
authors.forename: Virginia
authors.initials: V
authors.lastname: Quevedo
authors.forename: Dionisio L
authors.initials: DL
authors.lastname: Lorenzo
authors.forename: Fátima
authors.initials: F
authors.lastname: Batista
authors.forename: Marta
authors.initials: M
authors.lastname: Riaño
authors.forename: Francisco J
authors.initials: FJ
authors.lastname: Nóvoa
mesh_terms: D000368:Aged; D053299:Apolipoprotein B-100 / Q000097:blood*; D001266:Atlantic Islands / Q000453:epidemiology; D015415:Biomarkers / Q000097:blood; D002318:Cardiovascular Diseases / Q000150:complications / Q000453:epidemiology / Q000517:prevention & control*; D015331:Cohort Studies; D003430:Cross-Sectional Studies; D003924:Diabetes Mellitus, Type 2 / Q000150:complications*; D003925:Diabetic Angiopathies / Q000150:complications / Q000453:epidemiology / Q000517:prevention & control; D058065:Diabetic Cardiomyopathies / Q000150:complications / Q000453:epidemiology / Q000517:prevention & control; D003928:Diabetic Nephropathies / Q000150:complications*; D016903:Drug Monitoring; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D006949:Hyperlipidemias / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D008297:Male; D017410:Practice Guidelines as Topic; D051436:Renal Insufficiency, Chronic / Q000150:complications*; D012306:Risk; D013030:Spain / Q000453:epidemiology
chemical_list: D053299:Apolipoprotein B-100; D015415:Biomarkers; D000960:Hypolipidemic Agents
keywords: Apolipoprotein B100; cardiovascular risk; lipid goals; low-density lipoprotein–cholesterol; non-high-density lipoprotein–cholesterol; type 2 diabetes